

# A prospective study using the KerraCel™ dressing on multiple wound types

<b>Submission date</b> 15/09/2021	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
<b>Registration date</b> 15/11/2021	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
<b>Last Edited</b> 20/11/2025	<b>Condition category</b> Injury, Occupational Diseases, Poisoning	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

### Background and study aims

The KerraCel™ dressing is a CE-marked product that has been on the market since 2013. It contains gelling fibers that can soak up the fluid that can be created by wounds on the skin. The aim of the study is to collect additional information on the dressing to show that it is working as intended.

### Who can participate?

Patients aged 22 years or older and being seen for these types of wounds: Oncology wounds, traumatic wounds, cavity wounds, skin donor site. Examples of these can be: Oncology - radiation burns, cancerous wounds or wounds that occur after surgical removal of cancer. Traumatic - abrasions (deep scrapes) or lacerations. Cavity - wounds in a cavity (such as abdomen or chest). Donor sites where skin has been removed for grafting.

### What does the study involve?

For patients who meet the requirements to participate, you will be seen 4 times in the office /clinic. On the first visit, you will have a picture taken of the wound and the dressing put over the wound. You will come in 2 additional times, approximately 7 days apart from each visit, to have another picture of the wound taken and another dressing placed over the wound. A final visit will occur (again approximately 7 days from the 3rd visit), where the dressing will be removed and another picture is taken. No surveys will be completed for this study and only small amounts of information such as medical history, medication use, and information about your wound will be collected.

### What are the possible benefits and risks of participating?

Possible benefits of the study are the wound dressing may help manage your wound healing, additional follow-up by the staff at the hospital since this is a study, use of a dressing not currently in use at the facility.

Possible risks of participating are the same risks that would occur for treating any open wound with a wound dressing: skin irritation, redness, possible infection, delay in wound healing. One possible risks for this type of dressing is some of the gel material could remain in the wound.

Where is the study run from?  
Wythenshawe Hospital (UK)

When is the study starting and how long is it expected to run for?  
April 2021 to June 2023

Who is funding the study?  
KCI® USA, Inc (now a part of 3M) (USA)

Who is the main contact?  
Mrs Lawrie Rogerson-Wynne, Lawrie.rogerson@mft.nhs.uk

## Contact information

### Type(s)

Public

### Contact name

Mrs Lawrie Rogerson-Wynne

### Contact details

Research Office, First floor, NIHR Research Building  
Wythenshawe Hospital  
Southmoor Road  
Manchester  
United Kingdom  
M23 9QZ  
+44 (0)161 291 4850  
Lawrie.rogerson@mft.nhs.uk

### Type(s)

Scientific

### Contact name

Mr Eric Synatschk

### Contact details

KCI USA, Inc.  
6203 Farinon Drive  
San Antonio  
United States of America  
78249  
+1 5126625943  
esynatschk@mmm.com

## Additional identifiers

### Clinical Trials Information System (CTIS)

Nil known

## **Integrated Research Application System (IRAS)**

288315

### **Protocol serial number**

KERA\_CEL-PMCF007, IRAS 288315, CPMS 47700

## **Study information**

### **Scientific Title**

A prospective, observational, Post Market Clinical Follow-up (PMCF) study in patients using 3M™ KerraCel™ Gelling Fiber dressing

### **Study objectives**

Current hypothesis as of 18/03/2022:

The aim of this study is to describe the population and indications of the KerraCel™ Dressing to demonstrate that the product is performing as expected and is safe specifically on the identified wound types, where it has been identified that additional evidence is needed to support the Clinical Evaluation Report (CER).

---

### **Previous hypothesis:**

The aim of this study is to describe the population and indications of the KerraCel™ Dressing to demonstrate that the product is performing as expected and is safe specifically on oncological and traumatic wounds, where it has been identified that additional evidence is needed to support the Clinical Evaluation Report (CER).

### **Ethics approval required**

Old ethics approval format

### **Ethics approval(s)**

Approved 23/04/2021, London-Westminster Research Ethics Committee (The Old Chapel, Royal Standard Place, Nottingham, NG1 6FS, UK; +44 (0)207 104 8388; westminster.rec@hra.nhs.uk), ref: 21/PR/0337

### **Study design**

Single center observational study

### **Primary study design**

Observational

### **Study type(s)**

Treatment

### **Health condition(s) or problem(s) studied**

Oncological wounds (e.g. radiation burns, cancerous wounds and surgical wounds once the cancerous tissue has been removed), traumatic wounds (e.g. abrasions and lacerations), cavity wounds (such as abdominal or thoracic) and wounds created from skin donor sites

### **Interventions**

Patients will be seen and evaluated by a clinician to determine if their wound is appropriate to be treated with the KerraCel™ dressing. If yes, the clinician will make general observations of the wound and then dress the wound. Pictures will be taken of the wound initially and at each dressing change.

Patients will be seen 4 times in the office/clinic. On the first visit, a picture is taken of the wound and the dressing put over the wound. At 2 additional visits, approximately 7 days apart from each visit, another picture of the wound is taken and another dressing is placed over the wound. A final visit will occur (again approximately 7 days from the 3rd visit), where the dressing will be removed and another picture taken.

## **Intervention Type**

Device

## **Phase**

Phase IV

## **Drug/device/biological/vaccine name(s)**

3M™ KerraCel™ Gelling Fiber Dressing

## **Primary outcome(s)**

Treatment-related adverse events measured using patient records up to the final visit (~21-28 days)

## **Key secondary outcome(s)**

Wound healing and wound bed preparation by visual inspection of at baseline, ~day 7, 14, 21-28:

1. Decrease in wound size (volume, area, or depth)
2. Increase in % of wound granulation tissue
3. Wound moisture evaluation defined as wound exudate levels indicated as optimal
4. Decrease in % of nonviable tissue

## **Completion date**

21/06/2023

# **Eligibility**

## **Key inclusion criteria**

Current inclusion criteria as of 18/03/2022:

1. Subjects who have been diagnosed with an oncological wound (e.g. radiation burns, cancerous wounds, and surgical wounds once the cancerous tissue has been removed), or traumatic wound (e.g. abrasions and lacerations), or cavity wound (wounds in a cavity) or skin donor site
2. Must be able to provide informed consent
3. Only one wound may be treated per subject for the study
4. Aged  $\geq 22$  years

---

Previous inclusion criteria:

1. Subjects who have been diagnosed with an oncological wound (e.g. radiation burns, cancerous wounds, and surgical wounds once the cancerous issue has been removed) or traumatic (e.g. abrasions and lacerations) wound.
2. Must be able to provide informed consent.

3. Only one wound may be treated per subject for the study.
4. Age  $\geq 22$  years.

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Mixed

**Lower age limit**

22 years

**Upper age limit**

100 years

**Sex**

All

**Total final enrolment**

48

**Key exclusion criteria**

Current exclusion criteria as of 18/03/2022:

1. Has a known allergy to the dressing material
2. Has a wound that has uncontrolled heavy bleeding
3. Wound or burn larger than 20 cm in any direction
4. Pregnant or breastfeeding

---

Previous exclusion criteria:

1. Has a wound that requires packing of a body cavity with the KerraCel™ dressing, per the manufacturer's instructions for use.
2. Has a wound that has not achieved hemostasis, per the manufacturer's instructions for use.
3. Wound or burn larger than 20cm in any direction.
4. Pregnant or breastfeeding.

**Date of first enrolment**

01/09/2021

**Date of final enrolment**

09/06/2023

**Locations****Countries of recruitment**

United Kingdom

England

**Study participating centre**

**Wythenshawe Hospital**

University of Manchester & Manchester University NHS Foundation Trust

Southmoor Road

Manchester

England

M23 9QZ

## Sponsor information

**Organisation**

KCI (United States)

**ROR**

<https://ror.org/00wc6ay63>

## Funder(s)

**Funder type**

Industry

**Funder Name**

Kinetic Concepts

**Alternative Name(s)**

Kinetic Concepts, Inc., KCI USA, KCI

**Funding Body Type**

Private sector organisation

**Funding Body Subtype**

For-profit companies (industry)

**Location**

United States of America

## Results and Publications

## Individual participant data (IPD) sharing plan

### IPD sharing plan summary

Not expected to be made available

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Basic results</a>			20/11/2025	No	No
<a href="#">HRA research summary</a>			28/06/2023	No	No